Last updated
Dihexa and Semax are both studied for cognition, but they sit at opposite ends of the risk/evidence spectrum. Dihexa is an engineered compound with an extraordinary potency claim and almost no human data; Semax is a neuropeptide with decades of clinical use behind it, in one country. The contrast is as much about evidence as mechanism.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | Dihexa | Semax |
|---|---|---|
| Origin | Engineered from angiotensin IV (WSU, Harding lab) | ACTH(4-10) analog (Russia) |
| Mechanism | Potentiates HGF signaling at c-Met → synaptogenesis | Induces BDNF / NGF; melanocortin signaling, no HPA activation |
| Signature claim | Synaptogenesis orders of magnitude beyond BDNF (preclinical) | Neurotrophic induction + monoaminergic tone |
| Typical route (research) | Oral (designed for it) | Intranasal |
| Clinical use | None — early-stage | Approved in Russia (stroke, cognition, optic-nerve disease) |
| Evidence base | Preclinical only; human safety uncharacterized | Decades of Russian clinical use; limited Western replication |
| FDA approval | None | None |
Dihexa came out of Joseph Harding’s group at Washington State University, engineered from angiotensin IV — a blood-pressure-hormone fragment that unexpectedly supported learning and memory — into a stabilized, orally active, brain-penetrant molecule. Its headline is potency: in the original preclinical assays it promoted new synapse formation at concentrations orders of magnitude below BDNF, working through the hepatocyte growth factor (HGF) / c-Met pathway rather than a classic neurotransmitter system. That is exactly what makes it interesting — and exactly why its safety is a genuine open question: a small molecule that powerfully drives cell-growth signaling has essentially no human characterization.
Semax is the opposite profile. A heptapeptide analog of ACTH(4-10), it induces neurotrophic factors (BDNF, NGF, trkB) and modulates dopaminergic and serotonergic tone without activating the stress (HPA) axis, and it has been used clinically in Russia for stroke, cognitive impairment, and optic-nerve disease for decades. Its weakness is not safety experience but replication: most controlled data are Russian-language, with limited independent Western confirmation. So the choice is a real trade-off — Semax offers a longer human track record with a thinner Western evidence base; dihexa offers a striking mechanism and potency with almost no human data at all.
These are not interchangeable, and the honest differentiator is evidence, not just mechanism. Semax is a neuropeptide with a long (if geographically narrow) clinical history and a neurotrophic-induction mechanism; dihexa is an early-stage synaptogenic compound with a remarkable preclinical potency claim via HGF/c-Met and an essentially uncharacterized human safety profile. Neither is FDA-approved. For a research reference, Semax is the better-documented of the two, and dihexa the more experimental. This page is a research and educational reference, not medical advice.
Dihexa is an engineered, orally active peptidomimetic derived from angiotensin IV that promotes synapse formation through the HGF / c-Met pathway, with very high preclinical potency but almost no human data. Semax is an ACTH(4-10) analog that induces neurotrophic factors (BDNF, NGF) and is used clinically in Russia for stroke and cognition. Different mechanisms, and very different amounts of human experience.
Semax — it has been used clinically in Russia for decades for stroke and cognitive disorders, though most controlled data are Russian-language with limited Western replication. Dihexa’s evidence is preclinical, and its human safety is essentially uncharacterized.
Its safety in humans is not established. Dihexa is an early-stage research compound that potently drives cell-growth (HGF / c-Met) signaling, and it has not been characterized in controlled human studies. Neither dihexa nor Semax is FDA-approved.
Dihexa is proposed to work by potentiating hepatocyte growth factor (HGF) signaling at the c-Met receptor to drive synaptogenesis. Semax induces neurotrophic factors (BDNF, NGF) and modulates monoaminergic tone without activating the stress axis. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between Dihexa and Semax — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.